Valion Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) on August 6, 2026, covering events occurring on July 31, 2026. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Antonio, Texas. The filing details the achievement of a development milestone under an Amended and Restated Exclusive License Agreement with Statera Biopharma, Inc. regarding the TLR5 agonist program (Entolimod) for Acute Radiation Syndrome (ARS).
Key Financial Metrics and Transaction Details
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics for the reporting period. The primary financial activity disclosed is a milestone payment obligation of $750,000 triggered by the validation of current inventory of materials for distribution and sales. To satisfy this obligation, the Company issued 1,287.8685 shares of Series A Preferred Stock ("Milestone Shares") to Statera and Avenue Venture Opportunities Fund, L.P. ("Avenue").
Material Changes and Milestone Obligations
The Company achieved its first development milestone under the license agreement. The filing outlines the following payment structure for the ARS indication:
- Validation of Inventory: $750,000 (Achieved on July 31, 2026).
- Filing of BLA with FDA for ARS: $1,000,000 (Future obligation).
- Total ARS Development Milestones: $1,750,000.
Additionally, the Amended and Restated License Agreement allows the Company to pay royalties and milestones in either cash or Company securities at its discretion. Future milestones for Subsequent Indications (e.g., Neutropenia) include payments ranging from $500,000 to $1,500,000 upon specific clinical and regulatory achievements.
Guidance, Risks, and Unusual Items
The Company entered into a Securities Purchase Agreement with Avenue to facilitate the issuance of the Milestone Shares. The Company is required to file a resale registration statement with the SEC within 60 calendar days of the closing date. The shares issued are "restricted securities" and are subject to conversion limitations; holders cannot convert if the resulting beneficial ownership exceeds a specified percentage (between 4.9% and 19.9%) of the total outstanding common stock. The filing notes that the Company remains liable for future milestone payments and royalties upon achieving subsequent development and commercialization goals.
Investor Verification Checklist
- Verify the terms of the Certificate of Designation for the Series A Non-Voting Convertible Preferred Stock to understand conversion limits and voting rights.
- Confirm the filing status of the resale registration statement required within 60 days of July 31, 2026.
- Review the full text of the Amended and Restated Exclusive License Agreement (Exhibit 10.1 to the June 25, 2025 8-K) for detailed royalty rates and adjustment mechanisms.
- Monitor the Company's cash position to assess its ability to fund future milestones if it elects to pay in cash rather than stock.
- Check for any subsequent filings regarding the exercise of the Exclusive Option for Subsequent Indications (Neutropenia, etc.).